ClinicalTrials.gg
CompletedNCT03639571Updated Apr 17, 2019

Phase I Study to Assess Irritation, Sensitization and Adhesion of a Novel Ibuprofen 200 mg TEPI Medicated Plaster

A Phase 1 interventional study of Ibuprofen 200 mg TEPI Medicated Plaster and Placebo TEPI Plaster in Healthy, sponsored by Medherant Ltd. Completed at 1 site in Bulgaria. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-17.

Sponsored by Medherant Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This trial will be conducted with the aim to investigate the dermal response (skin irritation, sensitization) and the adhesion of Ibuprofen 200 mg TEPI Medicated Plaster as compared to a Placebo TEPI Plaster in two phases:

Induction Phase: multiple dose application of one active and one placebo plaster on 5 consecutive days in which the plasters remain in place for 23 hours ± 30 min a day and Challenge Phase: single dose application of one active and one placebo plaster which remain in place for 48 hours ± 30 min.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Medherant Ltd is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subject
  • Age between 18 and 65 years
  • Physically and mentally healthy as judged by means of medical and standard laboratory examinations
  • Non-smokers or ex-smokers (stopped at least 6 months ago) with a smoking history of ≤5 pack-year equivalents (1 pack-year equivalent is equal to smoking 1 pack per day for 1 year*****) and non-users of other nicotine containing products, confirmed by urine cotinine test
  • Weight ≥ 60 kg and within the range (including the borders) of 18.0 to 30.0 kg/m2
  • given in written form.

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical trial at same time or within the preceding 90 days (calculated from the date of the final examination of the previous study)
  • Fertile women without reliable method. List of allowed medically accepted contraceptive methods and the allowed HRT (used at least 4 weeks prior entry visit and not to be changed for the duration of the study):
  • combination of 2 barrier methods: female/male condoms, diaphragms, spermicides
  • intrauterine devices (IUD): inert or copper-releasing or progestinreleasing IUD
  • hormonal methods: combined oestrogen/progestin injectable contraceptives, progestin only injectable contraceptives, Norplant implants, skin patches, NuvaRing®
  • Hormone Replacement Therapy (HRT)
  • voluntary sterilization (female tubal occlusion).
  • Randomisation into the present trial more than once
  • History of drug abuse or use of illegal drugs: use of soft drugs, e.g. marihuana within 6 months of screening or hard drugs, e.g. cocaine, amphetamines, phencyclidine within 1 year of screening
  • Alcohol abuse, i.e. regular use of more than 2 units of alcohol per day or 10 units per week or a history of alcoholism (one unit of alcohol equals 250 ml beer, 125 ml wine or 25 ml spirits) or recovered alcoholics
  • Positive drug screening and/or positive alcohol test at entry (screening) visit, or on Day -1, or on Day 19
  • Pregnant and/or nursing women. Positive pregnancy test at entry (screening) visit, or on Day -1, or on Day 19
  • Allergic diathesis or any allergic disease (i.e. asthma or bronchial hyper-reactivity, contact dermatitis)
  • Known allergy to sticking plaster or to the ingredients of the products
  • Dermatologic disease that might interfere with the evaluation of test site reaction
  • Active skin disease
  • Subjects with tattoos, sunburn, coloration, open sores or scars on site of application
  • Subject with excessive hair at site of plaster application
  • Intake of systemic drugs interfering with the immune system (e.g. antiinflammatories, , immune-suppressants or antihistamines) within 2 weeks before and during the study
  • Topical therapy with analgesics or corticosteroids or antihistamines at the application sites within 2 weeks before and during the study
  • Intake or administration of any systemic or topical medication (including prescribed medication, OTC medication, and especially use of ointments, gels or patches for skin application) within 2 weeks before entry (screening) visit and during the study
  • Use of topical products without medication at the application sites (including make-up, sunscreen, creams, lotions, powders, alcohol) from 7 days prior entry (screening) visit and during the study
  • Intensive UV-light exposure (sunbath) at the application sites within 2 weeks before entry (screening) visit and during the study
  • Use of tanning beds at the application sites within 2 weeks before entry (screening) visit and during the study
  • Any method of hair removal (e.g. waxing, shaving, epilating, laser) at the application sites from 7 days before entry (screening) visit and during the study
  • Presence or a history of clinically significant cardiovascular, renal, hepatic, pulmonary, metabolic, endocrine, haematological, gastrointestinal, neurological, psychiatric or other diseases (e.g. disorders such as lupus erythematosus)
  • Clinically significant illness within 4 weeks before entry (screening) visit and during the study
  • Positive serologic findings for (HIV) antibodies, surface antigen (HBsAg), and/or virus (HCV) antibodies [
  • Systolic blood pressure outside the range of 100 to 140 mmHg and/or diastolic blood pressure outside the range of 60 to 90 mmHg12 at entry (screening) visit
  • Heart rate outside the range of 50 to 90 beats/min at entry (screening) visit
  • Respiratory rate outside the range of 12-24 breaths/min at entry (screening) visit
  • Axillary body temperature outside the interval of 35.5 to 37.1°C at entry (screening) visit
  • Any clinically significant abnormality of the resting (12-lead) (i.e. AV block, 2° to 3°, sinus bradycardia, sick sinus syndrome, SA block)
  • Laboratory values outside normal range with clinical relevance at entry (screening) examination
  • Not fulfilling study specific restrictions and diet
  • Subjects who are known or suspected:
  • not to comply with the study directives
  • not to be reliable or trustworthy
  • not to be capable of understanding and evaluating the information given to them as part of the formal information policy (), in particular regarding the risks and discomfort to which they would agree to be exposed
  • to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the inconvenience they may be involved in
  • subject is a dependent person, e.g. a relative, family member, or member of the investigator's or sponsor's staff
  • subject is in custody or submitted to an institution due to a judicial order.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Test

    Ibuprofen 200mg TEPI medicated plaster

    Drug: Ibuprofen 200 mg TEPI Medicated Plaster

  • Placebo comparator
    Placebo

    Placebo TEPI Plaster

    Other: Placebo TEPI Plaster

Interventions

  • Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK

  • OtherPlacebo TEPI Plaster

    Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK

06

What researchers measure

Primary outcomes

  1. Mean Irritation Score

    Average of Dermal Response Scores Score Definition 0 - No evidence of irritation 1. - Minimal erythema, barely perceptible 2. - Definite erythema, readily visible; minimal oedema or minimal papular response 3. - Erythema and papules 4. - Definite oedema 5. - Erythema, oedema, and papules 6. - Vesicular eruption 7. - Strong reaction spreading beyond test site

    Time frame: 10 days

  2. Total Cumulative Irritation Score

    Sum of Dermal Response Scores - Score Definition 0 - No evidence of irritation 1. - Minimal erythema, barely perceptible 2. - Definite erythema, readily visible; minimal oedema or minimal papular response 3. - Erythema and papules 4. - Definite oedema 5. - Erythema, oedema, and papules 6. - Vesicular eruption 7. - Strong reaction spreading beyond test site

    Time frame: 10 dyas

Secondary outcomes

  1. Mean Combined Dermal Response Score

    Average of Dermal Response + Other Effects Score Dermal score - as explained above other effect score - Score Definition 0 - None observed 1. - Slight glazed appearance 2. - Marked glazing 3. - Glazing with peeling and cracking 4. - Glazing with fissures Film of dried serous exudates covering all or part of the plaster site Small petechial erosions and/or scabs

    Time frame: 10 days

  2. Total Combined Dermal Response Score

    Sum of Dermal Response Score and Other Effects Score Dermal Response score - As explained above Other effects score - As explained above

    Time frame: 10 days

  3. Combined Dermal Response Scores

    Combined Dermal Response Scores ≥2 Dermal response score - As explained above other effects score - as explained above

    Time frame: 10 days

07

Study locations

1 site
  • MHAT
    Sofia, Bulgaria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Oct 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2018
First posted
Aug 21, 2018
StartActual
Aug 9, 2018
Primary completionActual
Oct 25, 2018
CompletionActual
Oct 25, 2018
Last update
Apr 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03639571
Lead sponsor
Medherant Ltd
Collaborators
Cooperative Clinical Drug Research and Development AG (CCDRD AG)
Responsible party
Sponsor
First posted
Aug 21, 2018
Start date
Aug 9, 2018
Primary completion
Oct 25, 2018
Completion
Oct 25, 2018
Last update
Apr 17, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion